Holding place for old articles.
Venture capital firm Grotech Ventures has raised $225 million that it plans to invest in early-stage technology companies.
The $225 million round, called Grotech Ventures II, is the firm’s eight fund. The firm had originally planned to raise $220 million but expanded to include new investors, said Grotech Managing General Partner and Founder Frank Adams.
It’s true that, geographically speaking, Maryland is a small state. But as the old saying goes, “Good things come in small packages,” and that is especially true when it comes to the resources, advice and technical expertise that Maryland offers inventors and technology entrepreneurs.
From university laboratories and research centers (such as The Johns Hopkins Applied Physics Laboratory, University of Maryland’s Office of Technology Commercialization or University of Maryland – Baltimore City’s ACTiVATE) to state organizations (Maryland Biotechnology Center or the Department of Business and Economic Development), a wide variety of entities are working to help entrepreneurs develop and market their inventions.
If you’re a startup working on a product for the healthcare industry, Boston is the place to be. During a trip to Bean Town, I was curious to hear what startup founders found most challenging in a city so rich with resources. The usual gripes I usually hear elsewhere, like troubles with seed funding or FDA regulation, didn’t come up as much. Instead, these founders seemed to find the more personal elements of entrepreneurship most challenging. Many times, I found myself talking to people who had made a shift from working in tech or research to becoming a business owner.
The community realizes that, though. In addition to numerous startup accelerators and incubators, Boston is home to lots of collaborative startup space.
Local businesses have seen needed venture capital and loans in greater abundance in recent months.
The amount of venture capital investment funneled to Montgomery County and Washington-area companies in 2013’s first quarter jumped by 30 percent from the same period a year ago, according to a recent report.
The $286.3 million invested in local companies in the first three months was the most in the quarter in five years, according to the report from PricewaterhouseCoopers LLP and the National Venture Capital Association, based on data by Thomson Reuters.
Governor Martin O’Malley today officially launched data.maryland.gov – Maryland’s first statewide open data portal that will provide researchers, entrepreneurs, public servants and citizens with a wide variety of data to support transparency and innovation in government. Data such as vendor payments, vehicle accidents, licensed veterinary clinics, GIS mapping data, and per capita electricity consumption will all be made available and housed in a central place for the public.
The Governor made this announcement at a panel discussion hosted in conjunction with the Future of Information Alliance (FIA) – a transdisciplinary partnership between the University of Maryland, College Park and 10 founding partners. The panel featured “futurists” and over 120 students, entrepreneurs and public servants who spoke about the importance of big data to better serve and inform the public.
Benlysta, a drug to treat lupus, has received approval from European regulators to be marketed in Europe, the drug’s co-makers, Human Genome Sciences Inc. of Rockville, and GlaxoSmithKline, its London-based parent, announced.
The European approval came two days after Benlysta, the first new treatment developed for lupus in 50 years, was approved for use in Canada.
The University of Maryland School of Medicine is launching a $500 million fundraising campaign, the largest in the school’s history.
The school plans to officially launch the capital campaign, “Transforming Medicine Beyond Imagination,” at its annual gala May 11. The event is considered a critical fundraiser for the school’s research and clinical programs.
May 15, 2013 8:00am – 10:00am
Tower Club, Tysons Corner
Attracting and retaining key employees is a challenge every business faces, and government contractors know that a valuable contract can hinge on making the right staffing choices. Savvy government contractors also recognize the necessity to maximize human capital within the constraints of sequestration, continuing resolution and lowest price technically acceptable contracts.
You’re invited to this breakfast workshop to learn about powerful employee incentive compensation strategies that can provide significant competitive advantages for your business. These often underutilized plans can attract top quality employees through cash, equity and other equity-linked compensation methods. In addition to creating great work environments, innovative incentive plans allow government contractors to be successful amidst the current era of regulatory challenges.
Pluristem Therapeutics Inc. (Nasdaq:PSTI) (TASE:PLTR) today announced that its wholly owned subsidiary, Pluristem Ltd., has entered into an exclusive out-license agreement with United Therapeutics Corporation (Nasdaq:UTHR) for the use of Pluristem’s PLacental eXpanded (PLX) cells to develop and commercialize a cell-based product for the treatment of Pulmonary Hypertension (PH).
Under the terms of the agreement, United Therapeutics will receive exclusive worldwide licensing rights for the development and commercialization of the future product for treating PH patients. Pluristem will retain all manufacturing rights; participate in the pre-clinical and clinical trial activities, as well as provide the commercial grade product.
UK pharmaceuticals giant GlaxoSmithKline has unveiled an “open innovation” platform through which it will publish data from its clinical trials online so it can be analysed by external researchers.
The online system allows scientists to submit a to request access anonymised drug trial data. Each request will be judged a panel of external experts appointed by GSK, and applicants must agree to publish their own findings.
